Pfizer Assembling New Commercial Team For Move Into Dermatology

The big pharma is moving into a new therapy area – dermatology – as part of a three-pronged strategy in Inflammation & Immunology that also includes rheumatology and gastroenterology. Pfizer’s first product for dermatology, crisaborole for atopic dermatitis, could launch next year.

Pfizer Inc. is building a specialized dermatology sales force as it moves into the therapy area as part of a broader strategy in inflammation and immunology. The company could launch its first drug in dermatology – crisaborole for atopic dermatitis – early next year, and Pfizer expects the drug to anchor a dermatology franchise.

Crisaborole, which Pfizer acquired earlier this year with the acquisition of Anacor Pharmaceuticals Inc. for $5

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Dermatological

More from Therapy Areas

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By 

Vyepti revenues rise by nearly 70% in the first quarter.

China Biopharma Podcast

 
• By 

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.